Recent research has clearly implicated the ATX-LPA-LPA1-6 signaling axis in the development of metabolic disorders, including obesity, insulin resistance, and impaired glucose homeostasis, as well as cardiovascular disease. This evidence concerns the gene LPA and Other metabolic disease.